42 reports of this reaction
3.4% of all DEXTROMETHORPHAN POLISTIREX reports
#3 most reported adverse reaction
DIZZINESS is the #3 most commonly reported adverse reaction for DEXTROMETHORPHAN POLISTIREX, manufactured by Haleon US Holdings LLC. There are 42 FDA adverse event reports linking DEXTROMETHORPHAN POLISTIREX to DIZZINESS. This represents approximately 3.4% of all 1,242 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN POLISTIREX who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among DEXTROMETHORPHAN POLISTIREX users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for DEXTROMETHORPHAN POLISTIREX:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 42 FDA reports for DEXTROMETHORPHAN POLISTIREX. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.4% of all adverse event reports for DEXTROMETHORPHAN POLISTIREX, making it one of the most commonly reported side effect.
If you experience dizziness while taking DEXTROMETHORPHAN POLISTIREX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.